Breaking News

Somite Therapeutics, OmniaBio Inc. Partner on DMD Cell Therapy

Will leverage AI to advance Somite’s cell therapy flagship program.

Author Image

By: Charlie Sternberg

Associate Editor

Somite Therapeutics, a tech-bio company harnessing big data and AI to pioneer novel cell replacement therapies, and OmniaBio Inc., a technology-driven cell and gene therapy CDMO, have announced a cell therapy development and manufacturing collaboration for producing SMT-M01, Somite’s flagship program for Duchenne muscular dystrophy (DMD), a rare, severe genetic disorder characterized by progressive muscle degeneration and weakness.    The new collaboration leverages OmniaBio’s induced pluripot...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters